logo_image
Headline: Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta� (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients
Location: South San Francisco, CA, US
Post Date: Apr 8, 2021 3:00 AM
TAG ID: pznews221703
DocID: 202104088213339-en.xml
Word Count: approx. 2329 words
 
Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients
 
Please login to download this Story